L3VLUP
ProSign in

XENE · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

XENEJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • XENE
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterXENEJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 20211 holders, $14m31 holders, $25.3bn
Q2 20211 holders, $17m37 holders, $25.6bn
Q3 20212 holders, $20m40 holders, $24.1bn
Q4 20214 holders, $205m33 holders, $25.2bn
Q1 20226 holders, $215m35 holders, $28.2bn
Q2 20227 holders, $230m33 holders, $26.9bn
Q3 20227 holders, $330m36 holders, $25.4bn
Q4 20228 holders, $303m35 holders, $27.6bn
Q1 20239 holders, $259m42 holders, $24.5bn
Q2 20235 holders, $222m38 holders, $25.0bn
Q3 20237 holders, $220m37 holders, $18.9bn
Q4 202311 holders, $590m31 holders, $19.0bn
Q1 20246 holders, $396m32 holders, $19.7bn
Q2 20247 holders, $383m35 holders, $20.4bn
Q3 20247 holders, $428m28 holders, $22.3bn
Q4 20246 holders, $400m37 holders, $20.4bn
Q1 20255 holders, $343m32 holders, $20.5bn
Q2 20255 holders, $224m31 holders, $18.4bn
Q3 20255 holders, $415m32 holders, $23.7bn
Q4 20256 holders, $501m29 holders, $27.8bn
Q1 20268 holders, $1.3bn34 holders, $35.6bn
Q2 20269 holders, $1.2bn33 holders, $39.1bn
XENE

Xenon Pharmaceuticals Inc

Holders
7
Reported value
$428m
Buyers
3
Sellers
2

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
28
Reported value
$22.3bn
Buyers
13
Sellers
16

Breadth -3 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only XENE (2)

Capital World Investors, Moore Capital Management LP

Only JNJ (23)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Markel Group Inc, MFS Investment Management, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Walleye Capital LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →